Immunic, inc. reports year end 2023 financial results and provides corporate update

– significantly strengthened balance sheet in january 2024 with execution of three-tranche private placement of up to $240 million, extending cash runway into the third quarter of 2025 based on initial $80 million tranche – – evidence for neuroprotective activity of vidofludimus calcium from phase 2 calliper interim analysis, consistent across the entire progressive multiple sclerosis population and all subtypes; top-line calliper data expected in april 2025 – – phase 3 ensure program in relapsing multiple sclerosis ongoing – – expanded vidofludimus calcium patent portfolio  with additional new patents granted; exclusivity protection expected into 2041 in the united states, unless extended further – – webcast to be held today, february 22, 2024, at 8:00 am et – new york , feb. 22, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended december 31, 2023, and provided a corporate update. "immunic made remarkable progress throughout 2023, and these achievements were punctuated by the successful three-tranche private placement of up to $240 million, which we announced last month.
IMUX Ratings Summary
IMUX Quant Ranking